Singapore, Oct. 13 -- Theramex, a London-headquartered specialty pharmaceutical company dedicated to women and their health, and China-based Asieris Pharmaceuticals, a global innovative biopharmaceutical company focused on genitourinary tumours and women's health, have entered into an exclusive licensing agreement for APL-1702 (CEVIRA(R)) covering all countries in Europe, as well as Australia and New Zealand (ANZ) and Turkey, subject to certain conditions. Asieris retains the rights for the rest of the world.

APL-1702 is a photodynamic drug-device combination product being developed as a non-surgical treatment for cervical precancerous lesions associated with HPV, including cervical intraepithelial neoplasia. The product is designed to b...